Search Results

The company behind the hormone-free contraceptive Phexxi®, Evofem Biosciences, Inc. announced financial results for the first quarter of 2024.

Women’s health innovator Evofem Biosciences, Inc. announced a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman’s unique needs, to offer Phexxi®, the non-hormonal prescription vaginal gel FDA-approved to prevent pregnancy for those who choose to use an on-demand method of birth control.

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc.

The company behind Phexxi® vaginal gel, women’s health innovator Evofem Biosciences, Inc., announced financial results for the fourth quarter and year ended December 31, 2023.

Commercial-stage women’s health innovator Evofem Biosciences, Inc. announced that it has successfully renegotiated the rebate for Phexxi®, its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program.

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the Company’s lowest total operating expenses since becoming a commercial stage company in 2020.

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023.

Evofem Biosciences, Inc. today announced preliminary results for the third quarter of 2023, including sequential growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives.